Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

High-Throughput Patch Clamp Screening in Human α6-Containing Nicotinic Acetylcholine Receptors.

Armstrong LC, Kirsch GE, Fedorov NB, Wu C, Kuryshev YA, Sewell AL, Liu Z, Motter AL, Leggett CS, Orr MS.

SLAS Discov. 2017 Jul;22(6):686-695. doi: 10.1177/2472555217696794. Epub 2017 Mar 15.

2.

Electrophysiology-Based Assays to Detect Subtype-Selective Modulation of Human Nicotinic Acetylcholine Receptors.

Kirsch GE, Fedorov NB, Kuryshev YA, Liu Z, Armstrong LC, Orr MS.

Assay Drug Dev Technol. 2016 Aug;14(6):333-44. doi: 10.1089/adt.2015.688.

3.

Electronic cigarettes in the USA: a summary of available toxicology data and suggestions for the future.

Orr MS.

Tob Control. 2014 May;23 Suppl 2:ii18-22. doi: 10.1136/tobaccocontrol-2013-051474.

4.

Biomarkers of tobacco smoke exposure.

Mattes W, Yang X, Orr MS, Richter P, Mendrick DL.

Adv Clin Chem. 2014;67:1-45. doi: 10.1016/bs.acc.2014.09.001. Epub 2014 Nov 4. Review.

PMID:
25735858
5.

Systematic review and evaluation of web-accessible tools for management of diabetes and related cardiovascular risk factors by patients and healthcare providers.

Yu CH, Bahniwal R, Laupacis A, Leung E, Orr MS, Straus SE.

J Am Med Inform Assoc. 2012 Jul-Aug;19(4):514-22. doi: 10.1136/amiajnl-2011-000307. Epub 2012 Jan 3. Review.

6.

Validation of electronic urinary incontinence questionnaires.

Straus SE, Holroyd-Leduc J, Orr MS.

Can J Urol. 2010 Jun;17(3):5195-9.

PMID:
20566013
7.

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.

Hazarika M, Jiang X, Liu Q, Lee SL, Ramchandani R, Garnett C, Orr MS, Sridhara R, Booth B, Leighton JK, Timmer W, Harapanhalli R, Dagher R, Justice R, Pazdur R.

Clin Cancer Res. 2008 Sep 1;14(17):5325-31. doi: 10.1158/1078-0432.CCR-08-0308.

8.

Usability of a mobile electronic medical record prototype: a verbal protocol analysis.

Wu RC, Orr MS, Chignell M, Straus SE.

Inform Health Soc Care. 2008 Jun;33(2):139-49. doi: 10.1080/17538150802127223.

PMID:
18604757
9.

The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program.

Orr MS, Goodsaid F, Amur S, Rudman A, Frueh FW.

Clin Pharmacol Ther. 2007 Feb;81(2):294-7. Review.

PMID:
17259954
10.

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements.

MAQC Consortium, Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK, Puri RK, Schrf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK, Zhang L, Amur S, Bao W, Barbacioru CC, Lucas AB, Bertholet V, Boysen C, Bromley B, Brown D, Brunner A, Canales R, Cao XM, Cebula TA, Chen JJ, Cheng J, Chu TM, Chudin E, Corson J, Corton JC, Croner LJ, Davies C, Davison TS, Delenstarr G, Deng X, Dorris D, Eklund AC, Fan XH, Fang H, Fulmer-Smentek S, Fuscoe JC, Gallagher K, Ge W, Guo L, Guo X, Hager J, Haje PK, Han J, Han T, Harbottle HC, Harris SC, Hatchwell E, Hauser CA, Hester S, Hong H, Hurban P, Jackson SA, Ji H, Knight CR, Kuo WP, LeClerc JE, Levy S, Li QZ, Liu C, Liu Y, Lombardi MJ, Ma Y, Magnuson SR, Maqsodi B, McDaniel T, Mei N, Myklebost O, Ning B, Novoradovskaya N, Orr MS, Osborn TW, Papallo A, Patterson TA, Perkins RG, Peters EH, Peterson R, Philips KL, Pine PS, Pusztai L, Qian F, Ren H, Rosen M, Rosenzweig BA, Samaha RR, Schena M, Schroth GP, Shchegrova S, Smith DD, Staedtler F, Su Z, Sun H, Szallasi Z, Tezak Z, Thierry-Mieg D, Thompson KL, Tikhonova I, Turpaz Y, Vallanat B, Van C, Walker SJ, Wang SJ, Wang Y, Wolfinger R, Wong A, Wu J, Xiao C, Xie Q, Xu J, Yang W, Zhang L, Zhong S, Zong Y, Slikker W Jr.

Nat Biotechnol. 2006 Sep;24(9):1151-61.

11.

Evaluation of external RNA controls for the assessment of microarray performance.

Tong W, Lucas AB, Shippy R, Fan X, Fang H, Hong H, Orr MS, Chu TM, Guo X, Collins PJ, Sun YA, Wang SJ, Bao W, Wolfinger RD, Shchegrova S, Guo L, Warrington JA, Shi L.

Nat Biotechnol. 2006 Sep;24(9):1132-9.

PMID:
16964227
12.

Errata.

Orr MS.

Toxicol Mech Methods. 2006;16(4):243. doi: 10.1080/15376520600665260. No abstract available.

PMID:
20021050
13.

Toxicogenomics and cross-species biomarker discovery: applications in drug discovery and safety assessment.

Orr MS.

Toxicol Mech Methods. 2006;16(2-3):79-87. doi: 10.1080/15376520600558317.

PMID:
20021000
14.

Large-scale gene expression analysis in molecular target discovery.

Orr MS, Scherf U.

Leukemia. 2002 Apr;16(4):473-7. Review.

15.

Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells.

Magnet KJ, Orr MS, Cleveland JL, Rodriguez-Galindo C, Yang H, Yang C, Di YM, Jain PT, Gewirtz DA.

Biochem Pharmacol. 2001 Sep 1;62(5):593-602.

PMID:
11585056
16.

Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells.

Orr MS, O'Connor PM, Kohn KW.

J Natl Cancer Inst. 2000 Jun 21;92(12):987-94.

PMID:
10861310
17.

UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase.

Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM, Sausville EA, Silvestrini R, Watanabe N, Piwnica-Worms H, O'Connor PM.

J Biol Chem. 1998 Dec 11;273(50):33455-64.

18.
20.

An important role for the retinoblastoma protein in staurosporine-induced G1 arrest in murine embryonic fibroblasts.

Orr MS, Reinhold W, Yu L, Schreiber-Agus N, O'Connor PM.

J Biol Chem. 1998 Feb 13;273(7):3803-7.

21.

Influence of ionizing radiation on proliferation, c-myc expression and the induction of apoptotic cell death in two breast tumour cell lines differing in p53 status.

Watson NC, Di YM, Orr MS, Fornari FA Jr, Randolph JK, Magnet KJ, Jain PT, Gewirtz DA.

Int J Radiat Biol. 1997 Nov;72(5):547-59.

PMID:
9374435
22.

Ionizing radiation and teniposide increase p21(waf1/cip1) and promote Rb dephosphorylation but fail to suppress E2F activity in MCF-7 breast tumor cells.

Orr MS, Watson NC, Sundaram S, Randolph JK, Jain PT, Gewirtz DA.

Mol Pharmacol. 1997 Sep;52(3):373-9.

PMID:
9281598
23.

Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin.

Fornari FA Jr, Jarvis DW, Grant S, Orr MS, Randolph JK, White FK, Gewirtz DA.

Biochem Pharmacol. 1996 Apr 12;51(7):931-40.

PMID:
8651943
24.

Radiosensitization of HL-60 human leukaemia cells by bryostatin-1 in the absence of increased DNA fragmentation or apoptotic cell death.

Watson NC, Jarvis WD, Orr MS, Grant S, Gewirtz DA.

Int J Radiat Biol. 1996 Feb;69(2):183-92.

PMID:
8609454
25.

Transcriptional down-regulation of c-myc expression in the MCF-7 breast tumor cell line by the topoisomerase II inhibitor, VM-26.

Orr MS, Fornari FA, Randolph JK, Gewirtz DA.

Biochim Biophys Acta. 1995 Jun 9;1262(2-3):139-45.

PMID:
7599188
26.
27.

Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells.

Bunch RT, Povirk LF, Orr MS, Randolph JK, Fornari FA, Gewirtz DA.

Biochem Pharmacol. 1994 Jan 20;47(2):317-29.

PMID:
8304976
28.

Supplemental Content

Support Center